Showing results (191-200 of 531) with videos related to
Sort By:
Pageof 54
Neuroscience Letters|February 11, 1991
Neurochemical and behavioural features induced by chronic low dose treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset: implications for Parkinson's disease?H Russ, W Mihatsch, M Gerlach, et al.Pharmacology & Therapeutics|January 1, 1994
Oxidative stress: free radical production in neural degenerationM E Götz, G Künig, P Riederer, et al.Journal of Psychiatry & Neuroscience : JPN|January 1, 1995
Cholinergic neurotransmission seems not to be involved in depression but possibly in personalityJ Fritze, M Lanczik, E Sofic, et al.Journal of Neurology|January 11, 2003
Which factors influence therapeutic decisions in Parkinson's disease?H Baas, G Fuchs, I Gemende, et al.European Journal of Pharmacology|March 29, 1989
[3H]MK-801 binding sites in post-mortem human frontal cortexJ Kornhuber, F Mack-Burkhardt, M E Kornhuber, et al.Advances in Neurology|January 1, 1987
Terguride: partial dopamine agonist in the treatment of Parkinson's diseaseT Brücke, W Danielczyk, M Simányi, et al.European Journal of Pharmacology|June 13, 1996
Selegiline is neuroprotective in primary brain cultures treated with 1-methyl-4-phenylpyridiniumE Koutsilieri, T S Chen, W D Rausch, et al.Pharmacopsychiatry|May 1, 1990
Brofaromine (CGP 11 305 A) in treatment of depression: biological estimation of plasma concentrationsJ Fritze, T Becker, V Ziegler, et al.Handbook of Clinical Neurology|March 3, 2018
Neurochemical markers as potential indicators of postmortem tissue qualityJ Sian-Hülsmann, C-M Monoranu, E Grünblatt, et al.Journal of Neural Transmission. Supplementum|February 24, 2001
Impaired iron homeostasis in Parkinson's diseaseK L Double, M Gerlach, M B Youdim, et al.Pageof 54